BioSpace News Archive

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company) today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a corporate update conference call on Tuesday, March 19, 2024, at 4:30 PM Eastern Time.

Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

Biotheus Inc. and Hansoh Pharmaceutical Group Co., Ltd., China’s leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand their strategic collaboration, following their current partnership since 2022.

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi®.

Glaucoma Research Foundation (GRF) today announced a total of $2.5 million in annual research grants to support innovative research to cure glaucoma and restore vision.

Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”) today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, “Methods for Treating Alzheimer’s Disease,” with claims that cover the use of Trappsol® Cyclo™ for the prevention and treatment of early onset Alzheimer’s disease.

Cellipont Bioservices and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies.

NOWDiagnostics announced the appointment of Jody Douglas Berry, Ph.D. as chief scientific officer.